GEN-MKT-18-7897-A
Aug 14, 2018 | Blogs, Clinical | 0 comments
According to the American Clinical Laboratory Association, more than 7 billion clinical lab tests are performed in the U.S. every year. While mass spectrometry represents only a fraction of the clinical applications, there are a growing number of tests where mass spectrometry is becoming the analytical method of choice. This is particularly the case where accuracy is challenged by interference from other compounds, such as toxicology testing, therapeutic drug monitoring, and in the measurement of low-level endogenous steroids.
This trend shift is driven by the analytical specificity of mass spectrometry as well as the advancement of this technology along with the development of new applications. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is a particularly powerful, accurate, and robust technique for clinical diagnostics, especially for quantitative analysis of low concentration compounds. When comparing to conventional analytical techniques, the unique capabilities of mass spectrometry makes it is easy to see why mass spectrometry adoption is accelerating and beginning to play a prominent role in more areas of medicine.
As more labs make the move to mass spec, we look at the top five reasons why:
Clinical Mass Spec from SCIEX – Designed for Routine and Advanced DiagnosticsSCIEX In Vitro Diagnostic Medical Devices combine best-in-class mass spec instruments, intuitive software, and preconfigured methods*. Our solutions are fully backed by market leading service, support, and training to help guarantee your long-term success in adopting mass spec in your clinical lab. If you are:
Consider all the factors above, why is your lab waiting to save time, cut costs and support physicians with greater confidence and more accurate results? Learn More About How SCIEX Clinical Diagnostics Solutions Can Transform Your Clinical Lab >
SCIEX Diagnostics products are for in vitro diagnostic use. Product(s) may not be available in all countries. For information on availability, please contact your local representative. All other SCIEX products are for research use only. Not for use in diagnostic procedures.
It is no secret that (bio)pharmaceutical research and development is complex, both scientific and regulatory processes. Here is an overview of just some of the ways SCIEX is working to support these challenges.
In a recent webinar, available on demand, scientists Luiza Chrojan and Ryan Hylands from Pharmaron, provided insights into the deployment of capillary gel electrophoresis (CGE) within cell and gene therapy. Luiza and Ryan shared purity data on plasmids used for adeno-associated virus (AAV) manufacturing and data on AAV genome integrity, viral protein (VP) purity and VP ratios using the BioPhase 8800 system.
Last year, Technology Networks hosted two webinars that featured groundbreaking research utilizing SWATH DIA (data-independent acquisition) for exposomics and metabolomics. Researchers Dr. Vinicius Verri Hernandes from the University of Vienna and Dr. Cristina Balcells from Imperial College London (ICL) demonstrated how a DIA approach can be successfully implemented in small molecule analysis using the ZenoTOF 7600 system. Their innovative approaches highlight the potential of SWATH DIA to enhance the detection and analysis of chemical exposures and metabolites, paving the way for new insights into environmental health and disease mechanisms.
Posted by
You must be logged in to post a comment.
Share this post with your network